Altamira Therapeutics Ltd.

Good day and welcome to the Altamira Therapeutics full year 2024 financial results and business update call. Today's conference is being recorded. I would now like to hand the conference over to your first speaker. Please go ahead.

Good morning and welcome to the Altamira Therapeutics full year 2024 financial results and business update call. On today's call are Thomas Mayer, Altamira's founder, Chairman and Chief Executive Officer, and Covadonga Panera, Altamira's Chief Operating Officer. Earlier today, Altamira issued a news release with the full year 2024 financial results, as well as a business update. The release is available on the company's website at www.altamiratherapeutics.com and has been filed with the SEC. During today's call, the company will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating financial or business performance or strategies or expectations. Full looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments, and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include but are not limited to the timing and conduct of our clinical trials, the clinical utility of our product candidates, the timing or likelihood of regulatory filings and approvals, our intellectual property position, and our financial position, as well as those described in the risk factors section in our annual report on Form 20F and future filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing its views as of any subsequent date. While it may elect to update these forward-looking statements at some point in the future, It specifically disclaims any obligation to do so even if it's viewed to change. With that, I will now hand the call over to Ultimate Therapeutics CEO, Thomas Meyer.

Thank you, operator. Hello, everyone, and thank you for joining our full year 2024 financial results and business update call. I will kick off the call by providing an overview of recent corporate developments and an update of our corporate strategy. Our chief operating officer, Covadonga Panera, will then discuss the progress with our RNA delivery business. Finally, I will discuss our 2024 financials and outlook for 2025. Overall, 2024 brought progress in many regards for Altamira. With our RNA delivery programs, we continued to gain momentum as we could win two new partners for our X4 platform, managed to further improve our manufacturing process, and were able to demonstrate that the platform works also with circular RNA. The latter highlighted the platform's great versatility across different RNA modalities and could help to open interesting new business opportunities for Altamira. Unfortunately, there was also a major setback in 2024 as NASDAQ decided to delist our common shares due to an issue with their minimum bid price rules. Also, we appealed against their decision and proposed taking customary measures to regain compliance. Our arguments fell on deaf ears, and the NASDAQ hearing panel upheld the listing decisions. Therefore, trading in our common shares was transferred to OTCQB and the ticker symbol changed from CITO to CITO-F. The transfer and the changes in valuation and trading volume related to this triggered our board to perform an intense review of the company's funding needs and options. We concluded that raising funding for the expected growth of the RNA delivery business from public markets was not a viable option. Rather, the board decided to prepare the involvement of private equity investors at the level of the company's Swiss subsidiary Altamira Therapeutics AG, short ATAG, which operates Altamira's RNA delivery business. Altamira aims to spin off a majority of ATAG's share capital and has initiated the process for the legal and organizational carve-out of this entity. With the partial spin-off, we anticipate the publicly listed Altamira Therapeutics Limited becoming even more of a holding company, owning minority stakes in ATAG and Altamira Medica the manufacturer of the Bencho nasal spray, and participating in their expected growth and value appreciation. In addition, the listed parent company stands to benefit from the partnering of the other legacy assets, such as AM125, our nasal spray for vertigo treatment, or AM111, a treatment for acute hearing loss. Following this introduction and update, I'm handing the call over to Kova Donga Panjira, our Chief Operating Officer, who will provide you with a more detailed update on our RNA delivery business. Kova?